These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 16163538

  • 1. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
    Press RR, Buckle T, Beijnen JH, van Tellingen O.
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
    [Abstract] [Full Text] [Related]

  • 2. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.
    Lagas JS, Damen CW, van Waterschoot RA, Iusuf D, Beijnen JH, Schinkel AH.
    Mol Pharmacol; 2012 Oct; 82(4):636-44. PubMed ID: 22767610
    [Abstract] [Full Text] [Related]

  • 3. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
    Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H, Beijnen JH, Schinkel AH.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6125-32. PubMed ID: 17062689
    [Abstract] [Full Text] [Related]

  • 4. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
    van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, Schinkel AH.
    Cancer Res; 2009 Dec 01; 69(23):8996-9002. PubMed ID: 19920203
    [Abstract] [Full Text] [Related]

  • 5. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
    Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O.
    Clin Cancer Res; 2000 Nov 01; 6(11):4416-21. PubMed ID: 11106262
    [Abstract] [Full Text] [Related]

  • 6. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats.
    Li C, Li X, Choi JS.
    Arch Pharm Res; 2009 Jan 01; 32(1):133-8. PubMed ID: 19183886
    [Abstract] [Full Text] [Related]

  • 7. Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats.
    Li X, Choi JS.
    Anticancer Res; 2009 Apr 01; 29(4):1411-5. PubMed ID: 19414395
    [Abstract] [Full Text] [Related]

  • 8. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
    Chen M, Xu D, Hu XL, Wang H.
    Clin Exp Pharmacol Physiol; 2008 Mar 01; 35(3):287-94. PubMed ID: 17973928
    [Abstract] [Full Text] [Related]

  • 9. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.
    Zhang Y, Hsieh Y, Izumi T, Lin ET, Benet LZ.
    J Pharmacol Exp Ther; 1998 Oct 01; 287(1):246-52. PubMed ID: 9765344
    [Abstract] [Full Text] [Related]

  • 10. Oral versus intravenous vinorelbine: clinical safety profile.
    Gebbia V, Puozzo C.
    Expert Opin Drug Saf; 2005 Sep 01; 4(5):915-28. PubMed ID: 16111453
    [Abstract] [Full Text] [Related]

  • 11. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.
    Dufek MB, Knight BM, Bridges AS, Thakker DR.
    Drug Metab Dispos; 2013 Mar 01; 41(3):642-50. PubMed ID: 23288866
    [Abstract] [Full Text] [Related]

  • 12. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes.
    Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, Schuetz JD, Schinkel AH.
    Mol Pharmacol; 2000 Jan 01; 57(1):188-97. PubMed ID: 10617694
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
    Bourgeois H, Vermorken J, Dark G, Jones A, Fumoleau P, Stupp R, Tourani J, Brain E, Nguyen L, Lefresne F, Puozzo C.
    Cancer Chemother Pharmacol; 2007 Aug 01; 60(3):407-13. PubMed ID: 17541591
    [Abstract] [Full Text] [Related]

  • 14. Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein.
    Bonhomme-Faivre L, Benyamina A, Reynaud M, Farinotti R, Abbara C.
    Addict Biol; 2008 Sep 01; 13(3-4):295-300. PubMed ID: 18331373
    [Abstract] [Full Text] [Related]

  • 15. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.
    van Waterschoot RA, Schinkel AH.
    Pharmacol Rev; 2011 Jun 01; 63(2):390-410. PubMed ID: 21490128
    [Abstract] [Full Text] [Related]

  • 16. Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
    Chu C, Abbara C, Noël-Hudson MS, Thomas-Bourgneuf L, Gonin P, Farinotti R, Bonhomme-Faivre L.
    Biochem Pharmacol; 2009 May 15; 77(10):1629-34. PubMed ID: 19426700
    [Abstract] [Full Text] [Related]

  • 17. P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin.
    Ito K, Nguyen HT, Kato Y, Wakayama T, Kubo Y, Iseki S, Tsuji A.
    J Control Release; 2008 Nov 12; 131(3):198-204. PubMed ID: 18725258
    [Abstract] [Full Text] [Related]

  • 18. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs.
    Kukanich B, Lascelles BD, Aman AM, Mealey KL, Papich MG.
    J Vet Pharmacol Ther; 2005 Oct 12; 28(5):461-6. PubMed ID: 16207309
    [Abstract] [Full Text] [Related]

  • 19. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
    Hirunpanich V, Murakoso K, Sato H.
    Int J Pharm; 2008 Mar 03; 351(1-2):133-43. PubMed ID: 18082981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.